Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might
Read MoreMany biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might
Read MoreBristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business.
Read MoreShares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the
Read MoreThe health care-focused hedge fund lists Yale University's endowment and the Tisch family among its clients. Source link
Read MoreCAR-T immunotherapies and antibody drug conjugates will highlight the American Society of Clinical Oncology's cancer research conference that starts Thursday.
Read MoreThese are the stocks posting the largest moves in midday trading. Source link
Read MoreNames on the move ahead of the open. Source link
Read More